drugset / Trial / NCT07064720

Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure

NCT07064720

Phase 2/3 Completed 60 enrolled Cairo University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow

Timeline

Start
2024-07-12
Primary completion
2025-12-22
Completion
2026-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1 ug/kg
Subject Mannitol Diagnostic / imaging agent 0.4 ug/kg
Subject Mannitol Diagnostic / imaging agent 0.5 g/kg

Indications

No indication recorded.